(PharmaNewsWire.Com, July 18, 2017 ) The growth of Influenza market is majorly driven by factors such as boost in Research & Development investment, rising public awareness, increase in healthcare expenditure, cost-effectiveness of immunization, introduction of new medicines, and increasing government initiatives for vaccination against influenza viruses. Additionally, a large section of population, especially in Asian and African countries are not immunized against influenza virus, thereby fueling the demand for the product in developing and under developed economies.
To give a brief idea Influenza or flu is a transmittable respiratory disease which affect nose, throat, and lungs. Influenza viruses are basically of three types-Type A (H1N1, H2N2, and H5N1, etc.), Type B, and Type C. It can be either seasonal, pandemic, or zoonotic. Influenza can be fatal if goes unnoticed and is regarded as a major reason of morbidity and mortality, globally. Some of the symptoms of influenza are fever, cough, sore throat, runny or stuffy nose, fatigue, headache, and body ache. According to World Health Organization, the flu occurs annually infecting 5% to 10% adults and 20% to 30% children, worldwide. Approximately, 3 to 5 million people gets severely infected resulting in 250,000 – 500,000 deaths. Children below 2 years of age and elderly above 65 years of age are at high risk of developing chronic flu.
Europe Influenza Market is segmented based on type and consumer as mentioned below for attaining a more granular perspective of the market. In the report each sub segment is provided with Market Size Estimations and Y-o-Y Forecasts.
Europe is an amalgamation of major economies like Germany, Spain, Italy, U.K. and France among others to name a few. The report justifies this by offering country wise data for the EU5 countries while taking some other predominant economies into consideration as well (Rest of Europe). The major companies dominating the Influenza Market are Sanofi-Pasteur (U.S.), AstraZeneca(United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), CSL Limited (Australia).
The Influenza market study offers the following deliverables: • Regional and country-level analysis that provides an innate perspective of European region and the aforementioned countries • Meticulously identifying the key areas of market growth by providing market size forecasts and y-o-y estimations at a Segment-level analysis • Explanations of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics • Study of macro and micro environmental factors that affect the European market presented in the form of PESTLE and Porter’s Five Forces Analyses • Company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and analyst overview of the key market players operating in the region • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies • Expertly devised Market Outlook - Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
About Market Data Forecast: The publisher of this report Market Data Forecast is well known for the services they render in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Europe among other regions of the global market as well, that too with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
